Item(by='sradman', descendants=None, kids=None, score=None, time=1604686334, title=None, item_type='comment', url=None, parent=25008445, text='I too tried to follow the progress of Apeiron&#x27;s APN01 which started to get news coverage at the end of February due to a University of British Columbia press release [1]. This pre-existing therapeutic was created out of SARS-CoV-1 research and I expected a SARS-CoV-2 trial to be accelerated. It never happened.<p>There is a story to be told here. Either a missed opportunity, incompetence, or a complete misunderstanding on my part of what a promising COVID-19 therapeutic looks like.<p>[1] <a href="https:&#x2F;&#x2F;www.med.ubc.ca&#x2F;news&#x2F;pilot-clinical-trial-in-china-to-test-ubc-researchers-findings-as-a-targeted-therapy-for-covid-19&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.med.ubc.ca&#x2F;news&#x2F;pilot-clinical-trial-in-china-to...</a>')